Effects of Cholinesterase Inhibitor Medication on QTc Interval in Memory Clinic Patients
| dc.contributor.author | Isotalo, Hanna Karita | |
| dc.contributor.author | Lehtovaara, Joanna Karoliina | |
| dc.contributor.author | Ekblad, Laura Linnea | |
| dc.contributor.author | Nuotio, Maria Susanna | |
| dc.contributor.author | Langén | |
| dc.contributor.author | Ville Lauri Johannes | |
| dc.contributor.organization | fi=PET-keskus|en=Turku PET Centre| | |
| dc.contributor.organization | fi=geriatria|en=Geriatrics| | |
| dc.contributor.organization | fi=sisätautioppi|en=Internal Medicine| | |
| dc.contributor.organization | fi=tyks, vsshp|en=tyks, varha| | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.14646305228 | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.27851436983 | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.40502528769 | |
| dc.contributor.organization-code | 2607304 | |
| dc.converis.publication-id | 498580773 | |
| dc.converis.url | https://research.utu.fi/converis/portal/Publication/498580773 | |
| dc.date.accessioned | 2025-08-28T01:38:39Z | |
| dc.date.available | 2025-08-28T01:38:39Z | |
| dc.description.abstract | <p><strong>Background:</strong> Cholinesterase inhibitors (ChEIs)-donepezil, rivastigmine, and galantamine-are beneficial in treating Alzheimer disease (AD). However, due to their impact on extra-cerebral acetylcholine signaling, concerns about cardiac adverse effects, including QT interval prolongation, persist. Despite this, evidence-based guidelines for electrocardiogram (ECG) monitoring during ChEI treatment are lacking, and prior studies on ChEIs and corrected QT intervals (QTc) yield inconsistent findings.<strong> </strong><br></p><p><strong>Objective:</strong> This study aimed to investigate the association between ChEI use and changes in QTc intervals among older adults.<strong> </strong><br></p><p><strong>Methods:</strong> We collected retrospective data from first-time visitors to the geriatric memory clinic of Turku City Hospital in 2017 and 2019. We included patients who were newly prescribed ChEIs and had ECG data available (n = 126, mean age 81.1 years, 56.3% female). QTc prolongation was defined as >= 460 ms in females and >= 450 ms in men. Paired t tests compared QTc means before and during ChEI use, and McNemar tests analyzed changes in the proportion of prolonged QTc. <br></p><p><strong>Results:</strong> Mean +/- SD QTc (ms) before versus during ChEI use was: 420.8 +/- 24.0 versus 423.9 +/- 28.0 (P = .13) for donepezil; 416.0 +/- 20.4 versus 416.5 +/- 26.1 (P = .92) for galantamine; 416.1 +/- 22.3 versus 409.6 +/- 20.1 (P = .30) for rivastigmine; and 419.7 +/- 23.4 versus 421.5 +/- 27.3 (P = .34) for all ChEIs. Prolonged QTc occurred in 7.9% of patients before versus 12.7% during ChEI use (P = .21). <br></p><p><strong>Conclusion and Relevance:</strong> We found no statistically significant association between ChEI use and QTc interval prolongation or an increased proportion of pathological QTc values during ChEI treatment. Larger studies are warranted to establish evidence-based recommendations on ECG monitoring during ChEI medication.</p> | |
| dc.identifier.eissn | 1542-6270 | |
| dc.identifier.jour-issn | 1060-0280 | |
| dc.identifier.olddbid | 207833 | |
| dc.identifier.oldhandle | 10024/190860 | |
| dc.identifier.uri | https://www.utupub.fi/handle/11111/57308 | |
| dc.identifier.url | https://journals.sagepub.com/doi/epub/10.1177/10600280251328530 | |
| dc.identifier.urn | URN:NBN:fi-fe2025082791781 | |
| dc.language.iso | en | |
| dc.okm.affiliatedauthor | Isotalo, Karita | |
| dc.okm.affiliatedauthor | Ekblad, Laura | |
| dc.okm.affiliatedauthor | Nuotio, Maria | |
| dc.okm.affiliatedauthor | Langen, Ville | |
| dc.okm.affiliatedauthor | Dataimport, tyks, vsshp | |
| dc.okm.discipline | 317 Pharmacy | en_GB |
| dc.okm.discipline | 317 Farmasia | fi_FI |
| dc.okm.internationalcopublication | not an international co-publication | |
| dc.okm.internationality | International publication | |
| dc.okm.type | A1 ScientificArticle | |
| dc.publisher | SAGE PUBLICATIONS INC | |
| dc.publisher.country | United States | en_GB |
| dc.publisher.country | Yhdysvallat (USA) | fi_FI |
| dc.publisher.country-code | US | |
| dc.publisher.place | THOUSAND OAKS | |
| dc.relation.doi | 10.1177/10600280251328530 | |
| dc.relation.ispartofjournal | Annals of Pharmacotherapy | |
| dc.source.identifier | https://www.utupub.fi/handle/10024/190860 | |
| dc.title | Effects of Cholinesterase Inhibitor Medication on QTc Interval in Memory Clinic Patients | |
| dc.year.issued | 2025 |
Tiedostot
1 - 1 / 1
Ladataan...
- Name:
- isotalo-et-al-2025-effects-of-cholinesterase-inhibitor-medication-on-qtc-interval-in-memory-clinic-patients.pdf
- Size:
- 1.58 MB
- Format:
- Adobe Portable Document Format